Harvard Bioscience, Inc.
HBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 1.02 | -0.00 | 10.24 |
| FCF Yield | -1.31% | 5.16% | -0.38% | -0.03% |
| EV / EBITDA | -89.72 | 33.04 | 174.20 | 29.49 |
| Quality | ||||
| ROIC | -6.02% | 2.14% | -5.61% | 2.98% |
| Gross Margin | 58.18% | 58.86% | 53.66% | 56.90% |
| Cash Conversion Ratio | -0.12 | -4.11 | -0.12 | -4.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.00% | -1.90% | 3.54% | 0.78% |
| Free Cash Flow Growth | -110.28% | 2,775.11% | -427.71% | -101.01% |
| Safety | ||||
| Net Debt / EBITDA | -27.40 | 4.79 | 52.68 | 4.34 |
| Interest Coverage | -1.94 | 0.53 | -2.72 | 1.34 |
| Efficiency | ||||
| Inventory Turnover | 1.69 | 1.87 | 1.99 | 1.86 |
| Cash Conversion Cycle | 228.77 | 203.81 | 192.75 | 228.51 |